- Home
- Solutions
- About Us
- Contact Us
- Careers
Breast cancer is a devastating disease that has long challenged the medical community. At Alfa Cytology, our team of renowned researchers and clinicians has been at the forefront of this groundbreaking field, dedicated to unlocking the full therapeutic potential of poly (ADP-ribose) polymerase (PARP) inhibitors for breast cancer therapy.
PARP is involved in the repair of single-strand DNA breaks. It plays a significant role in maintaining genomic integrity, which is often compromised in cancer cells. Many breast cancers, particularly those associated with BRCA1 and BRCA2 mutations, exhibit deficiencies in homologous recombination repair. These mutations render cancer cells more reliant on PARP for survival and DNA repair.
Fig. 1 Mechanism of action of PARP inhibitor for breast cancer. (Demir Cetinkaya B., et al. 2022)
The therapeutic rationale for the use of PARP (poly(ADP-ribose) polymerase) inhibitors in the treatment of breast cancer is primarily based on the concept of "synthetic lethality" and the unique vulnerabilities of cancer cells harboring deficiencies in DNA repair pathways.Breast tumors with deficiencies in the homologous recombination (HR) DNA repair pathway, such as those with BRCA1 or BRCA2 mutations, are particularly vulnerable to the inhibition of PARP. People with BRCA-mutated breast cancer have a deficiency in the HR pathway, making them particularly susceptible to the cytotoxic effects of PARP inhibition.
The remarkable efficacy and favorable safety profile of PARP inhibitors have made them a new addition to the breast cancer treatment landscape, especially for patients with BRCA gene mutations. Researchers are actively exploring combination strategies to further improve the efficacy of these targeted therapies. PARP inhibitors are currently being investigated in combination with other targeted therapies, chemotherapy and immunotherapy for the treatment of breast cancer.
| NCT | Therapy | Therapeutics | Phase |
| NCT05582499 | PARP inhibitor + CDK inhibitor | Fluzoparib + dalpiciclib/fluzoparib + chemotherapy |
|
| NCT05332561 | PARP inhibitor | Olaparib |
|
| NCT05761470 | PARP inhibitor + IO | Fluzoparib + camrelizumab + chemotherapy |
|
| NCT02849496 | PARP inhibitor + IO | Olaparib + atezolizumab |
|
| NCT04481113 | PARP inhibitor + CDK inhibitor | Niraparib + abemaciclib |
|
| NCT05834582 | PARP inhibitor | Fluzoparib + chemotherapy |
|
| NCT03911453 | PARP inhibitor | Rucaparib |
|
| NCT05498155 | PARP inhibitor + IO | Olaparib ± durvalumab |
|
| NCT045842555 | PARP inhibitor + IO | Olaparib ± durvalumab |
|
Through innovative research and advanced technology, Alfa Cytology delves into the mechanisms of PARP action and has the ability to help clients develop novel PARP inhibitors, as well as optimize the effectiveness of PARP inhibitors and identify their biomarkers, to accelerate the development of new breast cancer therapies.
Custom Therapeutic Peptide Synthesis
Cell-based Analysis
Breast Cancer Cell Lines
MCF-7, MCF10, T47D, T69, T73, T78, BT474, ZR75.1, SKBR3, UACC-893, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDA-MB-134-VI, MDA-MB-436, BT20, HCC38, HCC1937, HCC1806, SUM149, SUM159, SUM1315, SUM-44 PE, SUM225CWN, SUM102PT, IPH-926, LA-PDX1, BCM-3561, HCI-005, HMT-3522, 21T, h.DCIS.01, Hs578T, 4T1, 4T-1-LUC, EMT-6.
Breast Cancer Animal Models
At Alfa Cytology, we are committed to advancing the field of breast cancer treatment through the development of cutting-edge PARP inhibitor therapies. If you are interested in exploring our services or collaborating on PARP inhibitor research, please don't hesitate to contact us. We are eager to discuss how we can support your research efforts and contribute to the ongoing progress in breast cancer care.
Reference
For research use only. Not intended for any clinical use.
